Skip to main content
TXG
NASDAQ Industrial Applications And Services

10x Genomics 10-Q: Q3 Revenue $150.7M, Gross Margin Jumps to 75%, Cash $575.7M

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Health Tech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$57.61
Mkt Cap
$7.565B
52W Low
$12.8
52W High
$102.81
52W Position info
350% above low
Off High info
44% below high
Rel. Volume info
1.7× avg
Market data snapshot near publication time

TXG has more than doubled off its 52-week low of $12.8.

Summary

10x Genomics' Q3 10-Q shows revenue of $150.7M, a narrower $19.4M net loss and gross margin up to 75%, with $575.7M in cash and securities. New Xenium patent litigation and a $4.862M Scale Bio jury award headline the legal disclosures.


Key Events · Earnings and Guidance · TXG

  • Q3 Revenue $150.7M, Loss Narrows

    Revenue rose to $150.7M from $149.0M a year ago, while net loss narrowed to $19.4M ($0.15 per share) from $27.5M ($0.22).

  • Gross Margin Jumps to 75%

    Gross margin rose to 75% from 67%, driven by $5.9M lower inventory write-downs and $5.3M lower manufacturing costs.

  • Cash and Securities $575.7M

    Cash, cash equivalents and marketable securities totaled $575.7M, up $52.3M since December 31, 2025; nine-month operating cash flow was $58.9M versus $95.3M a year ago.

  • New Xenium Patent Suit

    Spatial Genomics and Caltech sued in August 2026 alleging the Xenium platform infringes five patents, seeking injunctive relief and unspecified damages; 10x counterclaimed in October 2026.


Analysis · TXG · Industrial Applications And Services

The 10-Q confirms the Q3 beat already flagged in the 2026-11-05 press release, but the detail is what matters: gross margin rose to 75% from 67% on lower inventory write-downs and manufacturing costs, and the balance sheet holds $575.7M in cash and securities. Against that, nine-month operating cash flow fell to $58.9M from $95.3M a year ago, and the legal docket expanded with a new Spatial Genomics/Caltech suit against Xenium and a Waters injunction request in Europe. The Scale Bio jury verdict against Parse ($4.862M awarded, willful infringement) is a potential upside but is under post-trial motions.

How filings like this one have moved

In the 30 days to Nov 6, 2026, 35.1% of the 2636 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, TXG was trading at $57.61 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $7.6B. The 52-week trading range was $12.80 to $102.81. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

TXG - Latest Insights

TXG
Nov 05, 2026, 4:05 PM EST
Source: PR Newswire
Importance Score:
8
Price at Filing: $57.72
Real-time Price: $61.20 info
Change: +$3.48 (+6%) info
Market Cap: $7.724B info
TXG
Sep 29, 2026, 9:00 AM EDT
Source: PR Newswire
Importance Score:
8
Price at Filing: $89.46
Real-time Price: $61.20 info
Change: -$28.26 (-32%) info
Market Cap: $7.724B info
TXG
Aug 06, 2026, 5:31 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $43.07
Real-time Price: $61.20 info
Change: +$18.13 (+42%) info
Market Cap: $7.724B info
TXG
Jun 09, 2026, 9:00 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $29.50
Real-time Price: $61.20 info
Change: +$31.70 (+107%) info
Market Cap: $7.724B info
TXG
May 07, 2026, 5:36 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $21.46
Real-time Price: $61.20 info
Change: +$39.74 (+185%) info
Market Cap: $7.724B info